Cargando…

Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates

Disruption of normal intrauterine brain development is a significant consequence of premature birth and may lead to serious complications, such as neonatal brain injury (NBI). This prospective case-control longitudinal study aimed at determining the levels and prognostic value of serum activin A dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Metallinou, Dimitra, Karampas, Grigorios, Lazarou, Eleftheria, Iacovidou, Nikoletta, Pervanidou, Panagiota, Lykeridou, Katerina, Mastorakos, George, Rizos, Demetrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468004/
https://www.ncbi.nlm.nih.gov/pubmed/34573263
http://dx.doi.org/10.3390/brainsci11091243
_version_ 1784573549256638464
author Metallinou, Dimitra
Karampas, Grigorios
Lazarou, Eleftheria
Iacovidou, Nikoletta
Pervanidou, Panagiota
Lykeridou, Katerina
Mastorakos, George
Rizos, Demetrios
author_facet Metallinou, Dimitra
Karampas, Grigorios
Lazarou, Eleftheria
Iacovidou, Nikoletta
Pervanidou, Panagiota
Lykeridou, Katerina
Mastorakos, George
Rizos, Demetrios
author_sort Metallinou, Dimitra
collection PubMed
description Disruption of normal intrauterine brain development is a significant consequence of premature birth and may lead to serious complications, such as neonatal brain injury (NBI). This prospective case-control longitudinal study aimed at determining the levels and prognostic value of serum activin A during the first three days of life in human premature neonates which later developed NBI. It was conducted in a single tertiary hospital and eligible participants were live-born premature (<34 weeks) neonates. Each case (n = 29) developed NBI in the form of an intraventricular haemorrhage, or periventricular leukomalacia, and was matched according to birth weight and gestational age to one neonate with normal head ultrasound scans. Serum activin A levels in both groups showed a stable concentration during the first three days of life as no difference was observed within the two groups from the first to the third day. Neonates diagnosed with NBI had significantly higher activin A levels during the first two days of life compared to control neonates and its levels correlated to the severity of NBI during the second and third day of life. Although serum activin A on the second day was the best predictor for neonates at risk to develop NBI, the overall predictive value was marginally fair (area under the ROC-curve 69.2%). Activin A, in combination with other biomarkers, may provide the first clinically useful panel for the early detection of premature neonates at high risk of NBI.
format Online
Article
Text
id pubmed-8468004
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84680042021-09-27 Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates Metallinou, Dimitra Karampas, Grigorios Lazarou, Eleftheria Iacovidou, Nikoletta Pervanidou, Panagiota Lykeridou, Katerina Mastorakos, George Rizos, Demetrios Brain Sci Article Disruption of normal intrauterine brain development is a significant consequence of premature birth and may lead to serious complications, such as neonatal brain injury (NBI). This prospective case-control longitudinal study aimed at determining the levels and prognostic value of serum activin A during the first three days of life in human premature neonates which later developed NBI. It was conducted in a single tertiary hospital and eligible participants were live-born premature (<34 weeks) neonates. Each case (n = 29) developed NBI in the form of an intraventricular haemorrhage, or periventricular leukomalacia, and was matched according to birth weight and gestational age to one neonate with normal head ultrasound scans. Serum activin A levels in both groups showed a stable concentration during the first three days of life as no difference was observed within the two groups from the first to the third day. Neonates diagnosed with NBI had significantly higher activin A levels during the first two days of life compared to control neonates and its levels correlated to the severity of NBI during the second and third day of life. Although serum activin A on the second day was the best predictor for neonates at risk to develop NBI, the overall predictive value was marginally fair (area under the ROC-curve 69.2%). Activin A, in combination with other biomarkers, may provide the first clinically useful panel for the early detection of premature neonates at high risk of NBI. MDPI 2021-09-20 /pmc/articles/PMC8468004/ /pubmed/34573263 http://dx.doi.org/10.3390/brainsci11091243 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Metallinou, Dimitra
Karampas, Grigorios
Lazarou, Eleftheria
Iacovidou, Nikoletta
Pervanidou, Panagiota
Lykeridou, Katerina
Mastorakos, George
Rizos, Demetrios
Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates
title Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates
title_full Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates
title_fullStr Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates
title_full_unstemmed Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates
title_short Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates
title_sort serum activin a as brain injury biomarker in the first three days of life. a prospective case—control longitudinal study in human premature neonates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468004/
https://www.ncbi.nlm.nih.gov/pubmed/34573263
http://dx.doi.org/10.3390/brainsci11091243
work_keys_str_mv AT metallinoudimitra serumactivinaasbraininjurybiomarkerinthefirstthreedaysoflifeaprospectivecasecontrollongitudinalstudyinhumanprematureneonates
AT karampasgrigorios serumactivinaasbraininjurybiomarkerinthefirstthreedaysoflifeaprospectivecasecontrollongitudinalstudyinhumanprematureneonates
AT lazaroueleftheria serumactivinaasbraininjurybiomarkerinthefirstthreedaysoflifeaprospectivecasecontrollongitudinalstudyinhumanprematureneonates
AT iacovidounikoletta serumactivinaasbraininjurybiomarkerinthefirstthreedaysoflifeaprospectivecasecontrollongitudinalstudyinhumanprematureneonates
AT pervanidoupanagiota serumactivinaasbraininjurybiomarkerinthefirstthreedaysoflifeaprospectivecasecontrollongitudinalstudyinhumanprematureneonates
AT lykeridoukaterina serumactivinaasbraininjurybiomarkerinthefirstthreedaysoflifeaprospectivecasecontrollongitudinalstudyinhumanprematureneonates
AT mastorakosgeorge serumactivinaasbraininjurybiomarkerinthefirstthreedaysoflifeaprospectivecasecontrollongitudinalstudyinhumanprematureneonates
AT rizosdemetrios serumactivinaasbraininjurybiomarkerinthefirstthreedaysoflifeaprospectivecasecontrollongitudinalstudyinhumanprematureneonates